

## CLAIM AMENDMENTS

### In The Claims:

1. (Currently Amended) A chemically modified ~~double stranded short interfering ribonucleic nucleic acid (siRNA)~~ molecule, comprising a complementary sense strand and antisense strand, wherein:
  - a. the nucleic acid molecule comprises a sense strand and a separate antisense strand, each strand having one or more pyrimidine nucleotides and one or more purine nucleotides;
  - b. said sense strand and said antisense strand are each strand of the nucleic acid molecule is independently [[about 14]] 18 to 28 27 nucleotides in length; and
  - c. said the antisense strand of the nucleic acid molecule comprises [[about 14 to 28]] 18 to 27 nucleotides that are complementary to a vascular endothelial growth factor receptor 1 (VEGFr1) nucleotide RNA sequence corresponding to comprising SEQ ID NO: 2752 or a portion thereof and vascular endothelial growth factor receptor 2 (VEGFr2) nucleotide RNA sequence corresponding to comprising SEQ ID NO: 2752 2753 or a portion thereof;
  - d. said the sense strand of said siRNA the nucleic acid molecule is complementary to the antisense strand and comprises a 18 to 27 nucleotide portion of said VEGFR1 and VEGFR2 RNA nucleotide sequence of about 18 to about 27 nucleotides; and
  - e. said siRNA molecule comprises at least one 2' O methyl or 2' deoxy 2' fluoro nucleotide. e. about 50 to 100 percent of the nucleotides in the sense strand and about 50 to 100 percent of the nucleotides in the antisense strand of the nucleic acid molecule are chemically modified with modifications independently selected from the group consisting of 2'-O-methyl, 2'-deoxy-2'-fluoro, 2'-deoxy, phosphorothioate and deoxyabasic modifications; and
  - f. one or more of the purine nucleotides present in one or both strands of the nucleic acid molecule are 2'-O-methyl purine nucleotides and one or more of the pyrimidine nucleotides present in one or both strands of the nucleic acid molecule are 2'-deoxy-2'-fluoro pyrimidine nucleotides.
2. (Canceled)

3. (Currently Amended) The siRNA nucleic acid molecule of claim 1, wherein said siRNA the nucleic acid molecule comprises one or more ribonucleotides.
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Canceled)
11. (Canceled)
12. (Canceled)
13. (Canceled)
14. (Currently Amended) The siRNA nucleic acid molecule of claim 1, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more of the purine nucleotides present in the sense strand are 2'-deoxy purine nucleotides.
15. (Currently Amended) The siRNA nucleic acid molecule of claim 1, wherein one 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more of the pyrimidine nucleotides present in the sense strand are 2'-deoxy-2'-fluoro pyrimidine nucleotides.
16. (Currently Amended) The siRNA nucleic acid molecule of claim 1, wherein the sense strand includes a terminal cap moiety at the 5'-end, the 3'-end, or both of the 5' and 3' ends of the sense strand.
17. (Currently Amended) The siRNA nucleic acid molecule of claim 16, wherein said terminal cap moiety is an inverted deoxy abasic moiety.
18. (Currently Amended) The siRNA nucleic acid molecule of claim 1, wherein one 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more of the pyrimidine nucleotides present in said the antisense strand are 2'-deoxy-2'-fluoro pyrimidine nucleotides.

19. (Currently Amended) The ~~siRNA nucleic acid~~ molecule of claim 1, wherein ~~one 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more of the~~ purine nucleotides present in ~~said the~~ antisense strand are 2'-O-methyl purine nucleotides.
20. (Currently Amended) The ~~siRNA nucleic acid~~ molecule of claim 1, wherein ~~one 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more of the~~ purine nucleotides present in ~~said the~~ antisense strand ~~comprise~~ are 2'-deoxy- purine nucleotides.
21. (Currently Amended) The ~~siRNA nucleic acid~~ molecule of claim 1, wherein said antisense strand comprises a terminal phosphorothioate internucleotide linkage at the 3' end of said antisense strand.
22. (Canceled)
23. (Canceled)
24. (Canceled)
25. (Canceled)
26. (Canceled)
27. (Canceled)
28. (Canceled)
29. (Canceled)
30. (Currently Amended) The ~~siRNA nucleic acid~~ molecule of claim 1, wherein the 5'-end of the antisense strand optionally includes a terminal phosphate group.
31. (Canceled)
32. (Canceled)
33. (Canceled)
34. (Canceled)
35. (Currently Amended) A composition comprising the ~~siRNA nucleic acid~~ molecule of claim 1 in a pharmaceutically acceptable carrier or diluent.

36. (New) The nucleic acid molecule of claim 1, wherein the chemically modified nucleic acid molecule is chemically modified with one or more phosphorothioate internucleotide linkage, 2'-O-methyl ribonucleotide, 2'-deoxy-2'-fluoro ribonucleotide, 2'-deoxy ribonucleotide, universal base nucleotide, 5-C-methyl nucleotide, inverted deoxyabasic or any combination thereof.
37. (New) The nucleic acid molecule of claim 1, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more of the pyrimidine nucleotides present in the sense strand are 2'-O-methyl pyrimidine nucleotides.
38. (New) The nucleic acid molecule of claim 19, wherein 1, 2, or 3 of the purine nucleotides present in the sense strand are 2'-O-methyl purine nucleotides.
39. (New) A method of inhibiting the expression of VEGFr1 and VEGFr2 comprising administering the nucleic acid molecule of claim 1 to a subject in need thereof under conditions that allow for inhibition of VEGFr1 and VEGFr2 expression.
40. (New) The nucleic acid molecule of claim 1, wherein the antisense strand, sense strand, or both the antisense strand and sense strand comprise a 3'-overhang of 1-3 nucleotides.
41. (New) The nucleic acid molecule of claim 40, wherein the nucleotides of the 3'-overhang are chemically modified.